DSM Pharmaceuticals has appointed Manja Bouman PhD as president and business unit director of its biopharm businesses at DSM Pharmaceutical Products. Bouman will head the DSM Biologics/BioSolutions businesses within the DSM Pharmaceutical Products business group of Royal DSM. Bouman will report to Lukas Utiger, president and CEO of DSM Pharmaceutical Products, as a member of the management team.
Bouman has a PhD in biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences and has held postdoctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In that role, Bouman was responsible for new business development and licensing & technology moving to Kiadis Pharma B.V. as CEO in 2004. Bouman was most recently CEO of Regenesance, a company that focuses on the development of monoclonal antibodies that inhibit MAC formation for treatment of chronic and acute neurological disorders.
Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large-and small-molecule API’s for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.
Source: DSM Pharmaceuticals